Phase 3 win for Protagonist Therapeutics with oral plaque psoriasis drug
The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition.
The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition.